EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Common Cabozantinib Adverse Events: Management and Impact on Outcomes and Treatment Duration in Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, and Radioiodine-Refractory Differentiated Thyroid Cancer

Steven Lee-Ramos, MS, RN, AGACNP-BC, Virginia Seery, MSN, RN, ANP-BC, AOCNP, Diane Andresen, MSN, APN-C, AOCNP, Denise Williamson, MPH, Nicholas Berry, PhD, Tasha Hall, PhD, RN, Brenda Martone, MSN, ANP-BC, AOCNP

Journal of the Advanced Practitioner in Oncology · 2026-11-09 · 17 (7)

DOI: 10.6004/jadpro.2026.17.7.30 ↗
AbstractBibliografische Angaben

Abstract

Background: Cabozantinib, a tyrosine kinase inhibitor, is a standard-of-care therapy for previously treated advanced renal cell carcinoma, hepatocellular carcinoma, and radioiodine-refractory differentiated thyroid cancer. We evaluated the impact of cabozantinib-associated adverse events (AEs) on treatment outcomes in these populations. Here we report our findings and discuss AE management. Methods: In this post-hoc analysis of three cabozantinib monotherapy pivotal studies (METEOR, CELESTIAL, and COSMIC-311), we compared progression-free survival (PFS) and treatment duration between patients who experienced ≥ 1 any-cause grade ≥ 3 AE and the overall population in the cabozantinib arm of each study. We characterized the most common any-cause AEs leading to dose modification, and advanced practitioner authors provided AE management strategies. Results: Of 923 cabozantinib-treated patients across the studies, the most common grade 3/4 AEs occurring in ≥ 10% of patients in all three studies combined were hypertension (15%), palmar-plantar erythrodysesthesia syndrome (13%), diarrhea (10%), and fatigue (10%). In each trial, median PFS was similar in patients with a grade ≥ 3 AE vs. the respective overall study populations; treatment durations were also similar. Among the four most common any-grade AEs leading to dose modifications, discontinuation rates due to each event were low (< 3%). Advanced practitioner–led AE management strategies included prophylaxis, monitoring, supportive care, and dose modifications. Conclusions: Cabozantinib has a consistent safety profile across indications. With proactive management, patients experiencing grade ≥ 3 AEs had similar PFS outcomes and treatment durations as the overall study populations. Advanced practitioner–led proactive AE management can allow patients to remain on therapy and maximize clinical benefits.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →